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Abstract
Purpose Glioblastoma (GBM) is the commonest brain tumour in adults. A sub-population of cells within these tumours, known
as cancer stem cells (CSCs), is thought to mediate their chemo-/radiotherapy resistance. CD133 is a cell surface marker that is
used to identify and isolate GBM CSCs. However, its functional significance, as well as the relevant microenvironment in which
to study CD133, have so far remained unknown. Here, we examined the effect of hypoxia on the expression of CD133 and on
that of the hypoxia-related factors HIF-1α and HIF-2α, and the potential functional significance of CD133 expression on the
acquisition of chemo-resistance by GBM cells.
Methods CD133, HIF-1α, HIF-2α, VEFG and (control) HPRT mRNA expression analyses were carried out on GBM cells
(U251, U87 and SNB19; 2D or 3D cultures) under both normoxic and hypoxic conditions, using qRT-PCR. siRNAwas used to
downregulate CD133, HIF-1α and HIF-2α expression in the GBM cells, which was confirmed by flow cytometry and qRT-PCR,
respectively. Drug sensitivity-related IC50 values were established using an Alamar Blue cell viability assay in conjunction with
the Graphpad prism software tool.
Results We found that the expression of CD133 was upregulated under hypoxic conditions in both the 2D and 3D GBM
cell culture models. In addition, an increased resistance to cisplatin, temozolomide and etoposide was observed in the
GBM cells cultured under hypoxic conditions compared to normoxic conditions. siRNA-mediated knockdown of either
HIF-1α or HIF-2α resulted in a reduced CD133 expression, with HIF-2α having a more long-term effect. We also found
that HIF-2α downregulation sensitized the GBM cells to cisplatin to a greater extent than HIF-1α, whereas CD133
knockdown had a more marked effect on cisplatin sensitisation than knockdown of either one of the HIFs, suggesting
the existence of a HIF-independent cisplatin resistance mechanism mediated by CD133. This same mechanism does not
seem to be involved in temozolomide resistance, since we found that HIF-1α downregulation, but not HIF-2α or CD133
downregulation, sensitized GBM cells to temozolomide.
Conclusions From our data we conclude that the mechanisms underlying hypoxia-induced CD133-mediated cisplatin resistance
may be instrumental for the design of new GBM treatment strategies.
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1 Introduction
Glioblastoma (GBM) is a World Health Organization (WHO)
defined grade IV astrocytoma, which is the most aggressive
form of glioma [1]. Despite notable achievements that have
been made in the past, the clinical management of GBM pa-
tients is still a major challenge [2], which may primarily be
attributed to its heterogeneous nature [3]. Temozolomide is an
oral alkylating agent that is able to traverse the blood-brain
barrier but, although promising results have been obtained in
the standard care for GBM [4–6], its efficacy ultimately di-
minishes due to the aquisation of resistance [7]. Cisplatin has
been used as neoadjuvant therapy with temozolomide [8] and
as adjuvant therapy with carmustine in patients withmalignant
gliomas [9]. In heavily pre-treated patients with relapsed high-
grade gliomas refractory to temozolomide alone, combina-
tions of temozolomide and cisplatin have been moderately
effective [10]. When used as a first-line chemotherapy with
fractionated temozolomide in chemotherapy-naïve patients
with recurrent GBM, it was found to result in a progression-
free survival (PFS) of 6 months [11]. Resistance to cisplatin
does, however, arise, potentially due to high levels of
glutathione-S-transferase (GST) activity [12]. Etoposide has
been found to improve the survival of patients with high-grade
glioma [13], but finally most patients succumb to GBM as a
result of relapse.
The tumour microenvironment consists of a myriad of
factors, including extracellular cellular matrix (ECM) com-
ponents [14] and variations in oxygen tension [15], that
may affect tumour biology. It has also been shown that
the ECM composition may affect cancer cell proliferation
and motility [16]. GBMs are characterized by regions of
hypoxia [17] ranging from 0.1% to 10% [18] which are
thought to play important roles in the aggressiveness of
the tumours [18]. As such, hypoxia has been considered
to serve as a biomarker for a poor prognosis, and to be
associated with radio-resistance and chemo-resistance, as
well as tumour cell migration and invasion [19]. Hypoxic
regions have also been shown to harbour GBM stem cell
populations [20]. Hypoxia inducible factors (HIFs) have
been postulated to be the primary mediators of hypoxic
responses [21]. The HIF factors HIF-1α and HIF-2α are
known to be able to bind to the same DNA sequence, re-
ferred to as hypoxia responsive element (HRE), and to
heterodimerise with HIF-1β to activate target genes.
However, HIF-1α and HIF-2α may also exhibit functional
differences, including different protein-protein interactions
[22] and tissue specificities [23]. HIF-1α has been found to
promote the survival of glioma cancer stem cells under
hypoxic conditions [24], and HIF-2α is thought to be
linked to the GBM stem cell phenotype within the hypoxic
niche [20]. Additionally, it has been found that in neuro-
blastoma cells exposed to hypoxia, the expression of HIF-
1α rapidly peaks and declines, whereas that of HIF-2α
remains steadily upregulated, thereby mediating a long
lasting response [23].
Since cancer stem cells (CSCs) have been implicated in
tumour recurrence and drug failure, their identification and
characterization is of therapeutic relevance [25, 26].
Several markers have been employed to differentiate
CSCs from the vast majority of cells within a tumour sam-
ple [27]. In GBM, CD133 is commonly used as a CSC
marker [28]. As yet, however, only a few studies have been
performed on the biological significance of CD133 in
GBM. In addition, the most appropriate environment in
which to study GBM cells has been contentious. Most as-
says used so far do not take into account the influence of
the tumour microenvironment (TME) and its role in regu-
lating CSC numbers and phenotypes. Tumour cells, includ-
ing GBM cells, are traditionally cultured in vitro with an
oxygen tension of 20%. Since this may not accurately re-
flect the behaviour of tumours in the in vivo situation, it
may explain why 95% of the anti-cancer drugs tested
in vitro have failed their translation to the clinic [29].
In the present study, we sought to understand the role of
hypoxia on CD133 expression, and whether or not HIFs play
any regulatory role in this expression. We also assessed the
role of hypoxia in etoposide and cisplatin chemo-resistance
and how HIF and CD133 downregulation may sensitize
GBM cells to chemotherapy. Our results strongly indicate that
CD133 upregulation under hypoxic conditions is mediated by
HIFs, with a longer-lasting effect of HIF-2α. In addition, we
found that CD133 knockdown sensitized GBM cells to cis-
platin in a HIF-independent manner.
2 Materials and methods
2.1 Cell lines and culture conditions
U87 cells were derived from the European Collection of
Authenticated Cell Cultures (ECACC), while U251 and
SNB19 cells were derived from the National Cancer Institute
USA (NCI-60). The GBM cells were grown under normoxic
(20% oxygen) or hypoxic (1% oxygen) conditions as standard
2D cultures or as Cultrex-based 3D cultures (Trevigen,
Gaithersburg, MD, USA).
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2.2 Quantitative real-time PCR
RNA extraction, cDNA synthesis and quantitative real-time
RT-PCR (qRT-PCR) were performed as previously reported
[30] using SYBR green (Eurogentec) for detection. The data
were expressed relative to the housekeeping gene HPRT and
calculated using the 2-ΔΔCt method. The primer sequences
used were: HPRT (F) 5’-ATTATGCTGAGGATTTGGAA
AGGG-3′ and (R) 5’-GCCTCCCATCTCCTTCATCAC-3′;
CD133 (F) 5’-CAATCTCCCTGTTGGTGATTTG-3′ and
(R) 5’-ATCACCAGGTAAGAACCCGGA-3′; VEGF (F)
5 ’ -CCAAGTGGTCCCAGGCTGCA-3 ′ and (R )
5’-TGGATGGCAGTAGCTGCGCT-3 ′ ; HIF1A (F)
5’-CCTCTGTGATGAGGCTTACCATC-3 ′ and (R)
5’-CATCTGTGCTTTCATGTCATCTTC-3′, HIF2A (F)
5 ’ - CCACCAGCTTCACTCTCTCC - 3 ′ a n d (R )
5’-TCAGAAAAGGCCACTGCTT-3′.
2.3 Small interfering RNA transfections
GBM cells were transfected with CD133, HIF-1α and HIF-2α
siRNAs (Eurogentec) using a Lipofectamine® RNAiMAX
Transfection Reagent (Life Technologies) according to man-





Cultrex basement membrane extract (BME; Trevigen) was
diluted to a concentration of 3 mg/ml on ice using phenol
red-free modified RPMI-1640 medium (Life Technologies).
Next, the cells were resuspended at appropriate densities and
seeded into black-walled, low-adherent, clear-bottom 96-well
culture plates (BrandTech) prewarmed to 37 °C.
2.5 Drug sensitivity assays
A cisplatin stock solution of 1 mg/ml was diluted to appropri-
ate concentrations. GBM cells were subsequently incubated
with drugs for 48 h after which an Alamar Blue cell viability
assay (Invitrogen) was carried out (10% v/v, 37 °C, 1 h). The
resulting fluorescence was measured using a fluorescence
plate reader (Flex-Station II, Molecular Devices, CA, USA)
and IC50 values were calculated relative to untreated cells
using the Graphpad prism software tool. Drug sensitivities
were calculated as percentages of matched untreated controls.
IC50 curves were plotted and values determined using
GraphPad Prism 6 (GraphPad Software Inc., USA; nonlinear
curve fit of Y = 100/ (1 + 10(LogIC50-X)*HillSlope).
2.6 Flow cytometry
After harvesting, GBM cells were spun down in
Eppendorf tubes and re-suspended in 80 μl buffer and
20 μl FcR blocker (Miltenyi Biotec), after which 10 μl
anti-CD133/1 (AC133)-PE antibody (Miltenyi Biotec) or
a mouse monoclonal IgG-PE isotype control was added
according to the manufacturer’s instructions. Next, the
cells were analysed using a Beckman Coulter flow
cytometer. The resulting data were analysed using
Weasel software (http:/ /www.frankbattye.com.au/
Weasel/).
2.7 Statistic analyses
Graphpad Prism version 6 was used to analyse all data. Data
comparisons were carried out using either Student’s t-test or
one-way ANOVA (Turkey’s multiple comparison test), when
appropriate.
3 Results
3.1 CD133 expression is increased over time following
exposure to hypoxia
To determine the effect of hypoxia on the expression of
CD133, we examined three glioblastoma (GBM)-derived
cell lines, U251, U87 and SNB19, cultured either in 2D or
3D under normoxic (20% oxygen) or hypoxic (1% oxy-
gen) conditions. We found that all three cell lines were
viable in both culture systems grown under both normoxic
and hypoxic conditions (Supplemental Fig. 1). We also
found that CD133 expression was higher under hypoxic
compared to normoxic conditions (Fig. 1a–c), with a sig-
nificant upregulation in the U251 and SNB19 2D models
and the SNB19 3D model after 48 h, respectively, using
qRT-PCR. In parallel, VEGF mRNA expression was found
to be induced (Supplemental Table 1A–C). This result is
indicative of an important role of the GBM microenviron-
ment in CD133 expression. An increase in hypoxia-
induced CD133 expression over time was subsequently
confirmed at the protein level using flow cytometry in
the 2D models (Fig. 1d, Supplemental Fig. 2). CD133 pro-
tein expression in the 3D cultures turned out to be techni-
cally challenging due to the time required to harvest cells
from the 3D matrix. We found that in U251 cells cultured
in 2D under normoxic or hypoxic conditions CD133 ex-
pression was rapidly lost (0 h, 15 min and 2 h measure-
ments). For cells grown in normoxia the CD133 protein
expression levels were found to be 14.9%, 6.9% and
4.4%, and that for cells grown in hypoxia 24.4%, 12.9%
and 5.1%, respectively (Fig. 2a, b).
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3.2 HIFs regulate CD133 expression
in a time-dependent manner
Since CD133 was found to be upregulated under hypoxic
conditions in both 2D and 3D GBM cell models, we next set
out to assess the mechanism by which CD133 is upregulated.
HIF-1α and HIF-2α are known to play important roles in
tumour progression under hypoxic conditions [21], but they
have not been studied exhaustively with respect to CD133
expression. After we found that through siRNA transfection
>57% HIF-1α and HIF-2α mRNA expression knockdown
was achieved in both the 2D and 3D models (Supplemental
Fig. 3A-C), we set out to assess CD133 expression in GBM
cells under hypoxic conditions. In the U251 2Dmodel follow-
ing 24 h exposure to hypoxia, which corresponds to a
mild/acute hypoxia exposure, we found that while HIF-1α
knockdown led to 63% CD133 expression downregulation,
little effect was noted after HIF-2α knockdown (Fig. 3a).
However, at later timepoints, corresponding to a chronic/
prolonged hypoxia exposure, we found that CD133 expres-
sion in the HIF-1α silenced cells started to return to baseline,
while in the HIF-2α silenced cells CD133 expression down-
regulation increased to 39% at 48 h and 69% at 72 h, respec-
tively (Fig. 3a). Similar results were obtained with U251
(Fig. 3b) and U87 cells (Supplemental Fig. 3D) cultured
in 3D. In parallel, we again observed VEGF expression
induction after HIF-1α or HIF-2α knockdown in the 3D
model (Supplemental Fig. 3E, F), suggesting a gradual shift
from a HIF-1α dependent to a HIF-2α dependent effect
after chronic hypoxia exposure.
Fig. 1 CD133 is upregulated under hypoxic conditions. U251 (a), U87
(b) and SNB19 (c) cells were cultured as 2D and 3D models under
normoxic (N) or hypoxic (H) conditions. CD133 mRNA levels were
quantified using qRT-PCR at the indicated times. The error bars represent
standard errors of means of the average of 3 independent experiments
with triple replicates per experiment for U251 and U87 and one experi-
ment for SNB19. One way ANOVA (Prism6) was used for statistical
comparison. ****p ˂ 0.0001 (d) Flow cytometric analysis of CD133 in
U251 cells cultured in 2D in a 96-well plate at a density of 10,000 cells/
well. The cells were divided into two sets: normoxia (left) and hypoxia
(right). For both sets, the total isotype control cell populations are pre-
sented based on side and scatter properties, and appropriate regions are
gated and used to compare cells stained with the anti-CD133 antibody.
The percentages of cells expressing CD133 after 24 to 72 h are indicated.
The analyses were performed using Weasel software
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3.3 GBM cells are resistant to chemotherapy
under hypoxic conditions
We next explored the effect of hypoxia on the cisplatin,
temozolomide and etoposide chemo-sensitivities of
GBM cells. We observed an increase in cisplatin resis-
tance in the three cell lines following exposure to hyp-
oxia compared to those cultured under normoxic condi-
tions (Fig. 4a, Supplemental Table 2A), but this increase
was only stat is t ical ly signif icant in U251 and
SNB19 cells. In addition, we observed increases in tem-
ozolomide resistance in the U87 and SNB19 cells, but
these increases were not statistically significant (Fig.
4b). No IC50 values could be obtained for etoposide
in the GBM cells under hypoxic conditions, even at
the highest concentration (267 μM) used (Fig. 4c,
Supplemental Table 2B). Therefore, we conclude that
all three GBM cell lines are >2-fold resistant to
etoposide under hypoxic conditions compared to
normoxic conditions (Fig. 4c, Supplemental Table 2B).
As HIFs are known to act as key mediators of hypoxia
(see above), we next investigated the effects of HIF-1α
and HIF-2α downregulation on GBM drug sensitivity.
Since we found that IC50 values for etoposide under
hypoxia could not be obtained, only sensitivities to cis-
platin and temozolomide were investigated. In doing so,
we found that HIF-2α downregulation, but not HIF-1α
downregulation, significantly sensitized U251 and U87
cells to cisplatin (Fig. 4d, Supplemental Fig. 4,
Supplemental Table 2C). In contrast, we found that
HIF-1α downregulation, but not HIF-2α downregulation,
significantly sensitized these GBM cells to temozolo-
mide, i.e., > 47% and 48% in U251 and U87, respectively
(Fig. 4e, f).
Fig. 2 CD133 protein
expression in U251 cells over
time. a Expression of CD133 in
U251 cells cultured in 2D under
normoxic (left column) and
hypoxic (right column)
conditions. In the top row (0) the
cells were stained immediately
after harvesting with EDTA. In
the middle row the cells were
stained 15 mins after harvesting.
In the bottom row the cells were
stained 2 hrs after harvesting. The
percentages of cells expressing
CD133 overtime are indicated. b
CD133 expression in U251 cells
over time and mean florescence
scores. The analyses were per-
formed using Weasel software
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3.4 CD133 downregulation sensitizes GBM cells
to cisplatin, but not temozolomide
Although HIF-1α and HIF-2α were found to be involved in
the regulation of CD133 expression under hypoxia, we noted
that their knockdown did not completely ablate CD133 ex-
pression, suggesting that its encoding gene may be regulated
by yet another mechanism(s). In addition we found that, while
HIF-1α affected the temozolomide sensitivity of GBM cells,
HIF-2α knockdown affected their cisplatin sensitivity.
Therefore, we next set out to investigate the possibility that
CD133, independently of HIFs, may be involved in temozo-
lomide and cisplatin resistance. Following CD133 expression
knockdown, we observed a 2-fold decrease in CD133 protein
expression as assessed by flow cytometry (Fig. 5a). This de-
crease did not result in sensitization of the different GBM cells
to temozolomide (Fig. 5b, Supplemental Fig. 5A).
Interestingly, however, we observed a significant 5-fold in-
crease in sensitivity to cisplatin in U251 cells (Fig. 5c,
Supplemental Table 3) and 2-fold increases in this sensitivity
in U87 and SNB19 cells (Supplemental Fig. 5B, C;
Supplemental Table 3). These results indicate that CD133
silencing enhances the efficacy of cisplatin in the treatment
of GBM.
4 Discussion
The emerging concept that tumour development largely relies
on signals derived from the tumour microenvironment (TME)
has led to a paradigm shift in cancer research [31]. Locally
advanced tumours are frequently characterized by hypoxia
resulting from abnormal micro-vessel structure and function,
and increased distances between blood vessels and tumour
cells [32]. Hypoxia is an important feature of the glioblastoma
(GBM) TME [20] and cells within their hypoxic niches have
been shown to be chemo-resistant [33]. Here, we observed
CD133 expression upregulation in GBM cells cultured in
2D and 3D models under hypoxic conditions and, although
largely consistent with other reports, different CD133 levels
were observed in the different GBM cells tested [25, 34].
CD133 expression upregulation under hypoxic conditions
has been reported before [35]. Our current data indicate that
hypoxia acts on GBM cells irrespective of whether they are
cultured in 2D or 3D. Although no significant CD133 upreg-
ulation was reached in the 3D model, a consistent higher level
of CD133 expression was observed when the cells were
grown in 3D, similar to what has recently been reported for
GBM cells grown in a 3D chitosan-alginate scaffold [36].
CD133 protein expression was also verified in the 2D models
using flow cytometry.We found, however, that this expression
rapidly decreased after harvesting of the cells, making it tech-
nically challenging to assess CD133 expression in the 3D
cultures, which require additional manipulations to free and
disaggregate the GBM cell clusters. This observationmay also
explain previous discrepancies noted in the analysis/sorting of
CD133 positive cell populations via flow cytometry and why
apparently CD133 negative cells may give rise to CD133
positive cells.
In both the 2D and 3D GBM cell models we found that
HIF-1α and HIF-2α knockdown led to a reduced CD133
expression. While the effect of HIF-1α silencing on CD133
expression diminished rapidly, we found that the effect of
HIF-2α silencing on CD133 expression became stronger over
time, similar to its effect on VEGF expression, which is a
knownHIF downstream target. This finding is in keeping with
a previous report on neuroblastoma cells [23]. The underlying
mechanism may involve the hypoxia-associated factor HAF,
which becomes upregulated during acute hypoxia and selec-
tively binds to HIF-1α, resulting in its degradation, while at
the same time HIF-2α transactivation and stability are promot-
ed [37]. SIRT1, a histone deacetylase, also appears to be in-
volved in this switch, i.e., it may deacetylate HIF-1α and
reduce its activity while enhancing HIF-2α-mediated tran-
scription through a HIF-dependent mechanism [38].
Fig. 3 HIF-1α and HIF-2α regulate CD133 expression in a time-
dependent manner. U251 cells were transfected with siRNAs specific
for HIF-1α or HIF-1α and subjected to hypoxia (1% oxygen) within 1 h
of transfection. At day 1 after transfection the cells were seeded into 96-
well plates at a density of 10,000 cells/well in 2D (a) or 3D (b). CD133
mRNA expression levels were monitored over time relative to non-
targeting siRNA controls. Error bars represent standard errors of the
means from 2 independent experiments in 2D and 3 independent exper-
iments in 3D
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Chemo-resistance plays a crucial role in GBM tumour
progression [39, 40] and it has been found that cells located
in its hypoxic regions are more resistant to chemotherapy
and may give rise to recurrences [17]. Our current results
also indicate that GBM cells become more resistant to tem-
ozolomide, cisplatin and etoposide under hypoxic condi-
tions. This, however, is not a universal finding. While in
one study breast cancer cells exposed to low oxygen levels
(< 0.1%) were also found to be resistant to a range of
chemotherapeutic agents, others have found differential re-
sponses of cells to therapeutic drugs under hypoxic condi-
tions, with cisplatin being more effective in hypoxic breast
cancer, small cell lung cancer and lymphoma cells com-
pared to the same cells maintained under normoxic condi-
tions [41]. The mechanism underlying this drug resistance
may be cell type dependent. In the breast cancer cells, it has
been found that enhanced resistance to cisplatin under hyp-
oxic conditions was mediated through HIF-1α [42], where-
as in osteosarcoma cells hypoxia-induced resistance to cis-
platin, doxorubicin and etoposide has been found to be
HIF-independent and to occur via hypoxia-driven attenua-
tion of p53 activation [43]. In the present study, we found
that siRNA-mediated HIF-1α knockdown, but not HIF-2α
knockdown, significantly sensitized GBM cells to temozo-
lomide. Others have similarly found that HIF-1α downreg-
ulation by BMP2 may increase the responsiveness of GBM
cells to temozolomide [44]. Our findings are also in agree-
ment with those from Li et al. who found that HIF-1α
silencing increases the sensitivity of tumour cells to temo-
zolomide in vivo [45].
Fig. 4 GBM cells are resistant
to chemotherapy when cultured
under hypoxic conditions.Mean
IC50 values (μM) for GBM cells
under normoxic and hypoxic
conditions following exposure to
cisplatin (a), temozolomide (b)
and etoposide (c) based on
Alamar Blue assays. Error bars
represent standard errors of the
means from 3 independent
experiments.*p < 0.05,
**p < 0.01,***p < 0.001 (Student
t-test). d After HIF-1α and HIF-
2α downregulation in U251 cells,
the mean IC50 values (μM) of
cisplatin were evaluated based on
Alamar Blue assays. Error bars
represent standard errors of the
means from 3 independent
experiments.*p < 0.05 (Student t-
test). e After HIF-1α and HIF-2α
downregulation, U251 cells were
treated with temozolomide after
which cell viabilities were
ascertained using Alamar Blue
assays. Error bars represent stan-
dard errors of means from 3 in-
dependent experiments.*p < 0.05,
ns = not significant. (f) Pattern of
IC50 shift to the left in U87 cells
following HIF-1α but not HIF-2α
downregulation. IC50 values for
etoposide were not achieved.
Values indicate the highest con-
centration used
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We also found that HIF-2α downregulation sensitized
GBM cells to cisplatin more effectively than HIF-1α down-
regulation, substantiating the differential roles of HIF-1α and
HIF-2α in tumour development [46]. This effect of HIF
downregulation on drug sensitivity was, however, relatively
small compared to the effect of CD133 downregulation,
which resulted in an increase in cisplatin sensitivity of at least
2-fold in all GBM cells tested and as much as 7-fold in U251
cells. In contrast, we found that CD133 downregulation did
not significantly affect the temozolomide sensitivity of GBM
cells. This latter observation is in accordance with that of
Perazzoli et al. who concluded from their results that CD133
was unrelated to temozolomide resistance [47], but disagrees
with others that have shown that CD133+ GBM cells are re-
sistant to temozolomide [48]. Our results suggest that the
hypoxia-induced cisplatin sensitivity of GBM cells may be
HIF independent and may be directly or indirectly induced
via CD133 activation. One potential mechanism for CD133-
dependent resistance may be CD133-mediated activation of
the Erk pathway, which has indeed been observed after
CD133 overexpression in GBM cells [49]. Interestingly, phos-
phorylation of the tyrosine-828 residue in the C-terminal cy-
toplasmic domain of CD133 has been found to mediate direct
interactions between CD133 and the phosphoinositide 3-
kinase (PI3K) 85 kDa regulatory subunit (p85), resulting in
preferential activation of the PI3K/protein kinase B (Akt)
pathway in GBM stem cells compared to matched non-stem
cells [50]. Therefore, upregulation of CD133 in GBM cells
under hypoxic conditions may lead to activation of the anti-
apoptotic Akt pathway, resulting in drug resistance [51].
Although cisplatin as a neoadjuvant agent, alone or in com-
bination with other agents including temozolomide, has been
explored and some benefits have been noted [8–11], eventu-
ally resistance may occur resulting in a poor clinical outcome.
Fig. 5 CD133 downregulation sensitizes glioblastoma cells to
cisplatin. a U251 cells were seeded in 6-well plates at a density of
500,000 cells/well. At day 0 the cells were transfected with either a
non-targeting siRNA (middle panel) or a CD133 specific siRNA (bottom
panel). Untransfected cells were also included as control (upper panel).
The cells were subjected to hypoxia at day 0 of transfection. At day 3 post
transfection, the cells were harvested and stained with an anti-CD133
antibody. The total population in the isotype control cells are presented
based on scatter properties in the dot plot (i, iii and v), and appropriate
regions were gated for the three sets of cells used to compare CD133
positive cells (ii, iv, and vi). CD133 expression levels as analysed by
Weasel software were 38.4% (ii), 29.8% (iv) and 14.9% (vi). The mean
fluorescence intensities of the positive cells are as presented in the plots.
A mouse monoclonal IgG was used as isotype control. b Following
CD133 downregulation, U251 cells were treated with temozolomide
and their viability ascertained using Alamar Blue assays. c Following
CD133 downregulation, U251 cells were treated with cisplatin and their
viability ascertained using Alamar Blue assays. Error bars represent stan-
dard errors of means from 3 independent experiments.*p < 0.05
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While HIF-dependent and HIF-independent mechanisms of
cisplatin resistance have previously been described, we iden-
tified a novel mechanism of hypoxia-induced cisplatin resis-
tance that is mediated via CD133. This mechanism may also,
at least partly, explain the observed association between
CD133 expression and a poor prognosis [52], and suggests a
role for CD133 as a functional molecule in its own right rather
than as a CSC marker. A further in-depth investigation of the
mechanism underlying this hypoxia-induced CD133-depen-
dent cisplatin resistance may facilitate the identification of
cisplatin combination therapies to improve its efficacy for
clinical use in neo-adjuvant and/or adjuvant settings.
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